FGEN FIBROGEN INC Insider Trading

CEO Thane Wettig bought 2,800 shares of KYNB at $7.09 on 2026-05-14; cross-ticker track record shows 100% win rate with avg 90d return +760.6%

Thane Wettig, CEO of Kyntra Bio, purchased 2,800 shares at $7.09, increasing his holdings by 11.5% to 27,203 shares. The transaction occurs in a context of significant business deterioration: annual revenue has contracted 78.3% and the company posted a net loss of $-15,198,000.00 against quarterly revenue of $3,738,000.00, indicating severe operational challenges. Notably, Wettig's cross-ticker track record across open-market buys shows a 100% win rate with an average 90-day return of +760.6%, though these prior outcomes span multiple tickers and may not predict results at Kyntra Bio. The current stock price of $7.13 remains 26.5% below the 52-week high, and recent momentum is modest (30-day change +1.9%, 90-day change +2.3%), presenting a material gap between the executive's demonstrated historical execution across other positions and the deteriorating fundamentals visible here.

CEO Thane Wettig bought 3,700 shares at avg $9.12 across 2 buys; stock at $8.70, down 55.0% from 52-week high.

Wettig Thane, CEO of FGEN, executed 2 separate open-market purchases totaling 3,700 shares for $33,749.73, expanding his stake by 17.4% to 24,939 shares. The blended average price of $9.12 contrasts sharply with the current price of $8.70 and the 52-week high of $19.31—the stock has declined 55.0% from its peak and 16.2% over the prior 30 days, situating this buy near recent lows. Notably, Wettig's prior two buys at FGEN (2025-03-24 and 2024-03-07) each posted strong 90-day returns of +2093.0% and +2021.1%, demonstrating a consistent pattern of well-timed accumulation at this ticker. However, underlying fundamentals are deeply troubled: annual revenue growth stands at -80.0%, quarterly revenue is just $1.1M, and the company posted a full-year net loss despite reporting $200.6M current-quarter net income (likely a restatement or one-time item that masks broader negative operations). The 0.16 P/E and $35.2M market cap reflect severe distress. This purchase by the CEO during a steep drawdown warrants examination of whether Wettig is accumulating at a capitulation point or responding to material developments not yet public.

Director Schoeneck James A bought 23,567 shares at $5.07; stock down 83.3% from 52-week high, but insider's prior FGEN trades delivered 90d returns of +2000.2% and +1933.4%.

Director Schoeneck James A purchased 23,567 shares at $5.07, increasing his holdings by 146.4% to 39,666 shares post-transaction in a heavily depressed stock (currently $5.25, -83.3% from 52-week high of $31.50). His cross-ticker track record across 2 prior buys shows an average 90d return of +1390.0% with a 100.00% win rate, and critically, his 2 prior purchases at FGEN on 2025-03-21 and 2025-03-20 each captured 90d returns exceeding +1900%, establishing a pattern of well-timed entry at this ticker. However, this purchase follows a 30-day and 90-day decline of -28.5% and -28.6% respectively, and the company's fundamentals have deteriorated: annual revenue growth is -80.0% and full-year net income was negative, though the latest quarter shows a reversal to $4.6M net income on $2.7M revenue. The concentration of prior buy expertise at this specific ticker (2 of 2 prior same-ticker trades were well-timed) contrasts sharply with the current macro weakness; investors should track whether this purchase represents a repeat of his earlier tactical entries or reflects material operational recovery obscured by recent price action.

FGEN CEO Wettig Thane bought 145,000 shares at $0.35 on 2025-03-24 (total $50.7K), increasing holdings 36.4% to 543.3K shares amid -87.0% decline from 52-week high.

CEO Wettig Thane purchased 145,000 shares at $0.35, the lowest price point in the company's 52-week trading range of $7.47–$66.00, representing a rare point of extreme distress given the stock's -87.0% decline from its 52-week peak and -51.5% drop over the past 30 days. This purchase occurred against a backdrop of severe operational deterioration: annual revenue declined -80.0%, the company posted a net loss of $17.1M on quarterly revenue of $46.3M, and remains unprofitable on a full-year basis. The CEO's prior buy at this same ticker on 2024-03-07 produced a +2021.1% 30-day return and +1484.3% 90-day return, establishing a pattern of well-timed accumulation at FGEN, yet the current environment presents markedly different risk: the company's collapsing revenue base and deepening losses create structural uncertainty about whether historically favorable recovery dynamics will repeat. The 36.4% increase in the CEO's holdings signals material conviction, but the deteriorating operational fundamentals merit investor scrutiny of the company's pathway to stabilization.

Director Schoeneck purchases 300,000 shares for $105,040.00 at $0.35–$0.34, raising stake 406.9%, as stock drops 47.8% in 30 days from $66.00 peak.

James A. Schoeneck, a director at FibroGen, executed 2 separate purchases totaling 300,000 shares for $105,040.00 on 2025-03-20 and 2025-03-21, expanding his holdings from 73,722 to 373,722 shares. The purchases occurred at prices ($0.35 and $0.34) far below the 52-week high of $66.00, and in a sharp drawdown period: the stock is -47.8% over the past 30 days and -86.0% from its peak. The company is unprofitable with annual revenue declining -80.0% year-over-year and posted a quarterly net loss of $-17,084,000.00 against revenue of $46,333,000.00. This material acquisition by a director during severe price deterioration and operational stress suggests confidence in mean reversion or value at current levels, but it occurs amid fundamental distress that warrants scrutiny of the company's path to profitability.